Výsledky vyhledávání

Akademický článek

Identification of a central network hub of key prognostic genes based on correlation between transcriptomics and survival in patients with metastatic solid tumors.

Autor: Lazar V; Worldwide Innovative Network Association-WIN Consortium, Villejuif, France., Raymond E; Groupe Hospitalier Saint Joseph, Oncology Department Paris, France., Magidi S; Worldwide Innovative Network Association-WIN Consortium, 24, rue Albert Thuret, Chevilly-Larue 94850, France., Bresson C; Worldwide Innovative Network Association-WIN Consortium, Villejuif, France., Wunder F; Worldwide Innovative Network Association-WIN Consortium, Villejuif, France., Berindan-Neagoe I; The Oncology Institute 'Prof. Dr. Ion Chiricuta,' Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania., Tijeras-Rabaland A; Groupe Hospitalier Saint Joseph, Oncology Department Paris, France., Raynaud J; Worldwide Innovative Network Association-WIN Consortium, Villejuif, France., Onn A; Sheba Medical Center, Institute of Pulmonology, Tel HaShomer, Ramat-Gan, Israel., Ducreux M; Gustave Roussy, Department of Medical Oncology, Villejuif, France.; University Paris-Saclay, Department of Medical Oncology, Orsay, France., Batist G; Segal Cancer Centre, Department of Oncology, Jewish General Hospital, McGill University, Montréal, QC, Canada., Lassen U; Rigshospitalet, Copenhagen, Denmark., Cilius Nielsen F; Rigshospitalet, Copenhagen, Denmark., Schilsky RL; Worldwide Innovative Network Association-WIN Consortium, Villejuif, France., Rubin E; Ben-Gurion University of the Negev, The Shraga Segal Department of Microbiology, Immunology & Genetics, Faculty of Health Sciences, Be'er-Sheva, Israel., Kurzrock R; Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Publikováno v: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2024 Oct 17; Vol. 16, pp. 17588359241289200. Date of Electronic Publication: 2024 Oct 17 (Print Publication: 2024).

Zobrazit plný text záznamu

Akademický článek

"Wunder" F-BAR domains: going from pits to vesicles.

Autor: Fütterer K; School of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. k.futterer@bham.ac.uk, Machesky LM

Publikováno v: Cell [Cell] 2007 May 18; Vol. 129 (4), pp. 655-7.

Zobrazit plný text záznamu

'Wunder' F-BAR domains: going from pits to vesicles

Autor: Klaus Fütterer, Laura M. Machesky

Publikováno v: Cell. 129(4)

Clathrin-mediated endocytosis is a key mechanism by which cells take up extracellular cargo. In this issue, Shimada et al. (2007) reveal the mode of action of the F-BAR domain, which deepens the initial membrane pit that forms during clathrin-mediate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6293d362d27303a010e17575406fea6d
https://pubmed.ncbi.nlm.nih.gov/17512409

Zobrazit plný text záznamu

Akademický článek

Identification and characterization of the new generation soluble guanylate cyclase stimulator BAY-747 designed for the treatment of resistant hypertension.

Autor: Wunder F; Lead Identification & Characterization, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany., Stasch JP; Cardiovascular Research, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany.; Institute of Pharmacy, University of Halle, Halle, Germany., Knorr A; Cardiovascular Research, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany., Mondritzki T; Cardiovascular Research, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany.; University of Witten/Herdecke, Witten, Germany., Brockschnieder D; Cardiovascular Research, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany., Becker-Pelster EM; Cardiovascular Research, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany., Sandner P; Cardiovascular Research, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany.; Institute of Pharmacology, Hannover Medical School, Hanover, Germany., Tinel H; Cardiovascular Research, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany., Redlich G; Pharmacokinetics, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany., Hartung IV; Synthetic Modalities, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany., Vakalopoulos A; Synthetic Modalities, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany., Follmann M; Synthetic Modalities, Pharma Research and Development Center, Bayer AG, Wuppertal, Germany.

Publikováno v: British journal of pharmacology [Br J Pharmacol] 2023 Oct; Vol. 180 (19), pp. 2500-2513. Date of Electronic Publication: 2023 Jun 20.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

New Generation of sGC Stimulators: Discovery of Imidazo[1,2- a ]pyridine Carboxamide BAY 1165747 (BAY-747), a Long-Acting Soluble Guanylate Cyclase Stimulator for the Treatment of Resistant Hypertension.

Autor: Vakalopoulos A; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Wunder F; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Hartung IV; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Redlich G; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Jautelat R; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Buchgraber P; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Hassfeld J; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Gromov AV; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Lindner N; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Bierer D; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Gries J; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Kroh W; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Paulsen H; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Mittendorf J; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Lang D; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Becker-Pelster E; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Brockschnieder D; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Geiss V; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Li V; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Straub A; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Knorr A; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Mondritzki T; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; University of Witten/Herdecke, 58455 Witten, Germany., Trübel H; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; University of Witten/Herdecke, 58455 Witten, Germany., Raschke M; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Schaefer M; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Lead Discovery, Nuvisan ICB GmbH, Muellerstrasse 178, 13353 Berlin, Germany., Thomas D; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany., Sandner P; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Department of Pharmacology, Hannover Medical School, 30625 Hannover, Germany., Stasch JP; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.; Institute of Pharmacy, Martin Luther University, 06120 Halle, Germany., Follmann M; Pharmaceuticals, Research and Development, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2023 Jun 08; Vol. 66 (11), pp. 7280-7303. Date of Electronic Publication: 2023 Apr 11.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání